Literature DB >> 7794305

An audit of the treatment of cancer of the oesophagus.

P M Sagar1, T Gauperaa, H Sue-Ling, M J McMahon, D Johnston.   

Abstract

The treatment of cancer of the oesophagus in The General Infirmary at Leeds between the years 1975 and 1988 was reviewed. All cases with histologically proved cancer of the oesophagus were included, data being obtained from case notes, theatre operation books, endoscopy records, pathology records, and the Yorkshire Cancer Registry. Three hundred and sixteen patients were identified. Demographic details, mode of presentation, preoperative investigations, surgical management, methods of palliation, and survival data were entered into a database. The male to female ratio was 3:2 and the median age at presentation was 69 years (range 35-96). Surgical exploration was carried out in 134 of 316 patients (42%). Resection of the tumour, whether curative or palliative, was possible in 106 of 134 patients (79%). Operative (30 day) mortality was 27%. In 22 of 134 patients (16%), only intubation of the tumour was possible, while six patients (5%) had a thoracotomy or laparotomy alone. Median survival of the 106 patients after surgical resection was 292 days (range 0-14.2 years) and seven of them (7%) were still alive five years later. Of the remaining 182 patients (58%) who were not operated upon, 36 patients (11%) had a radical course of radiotherapy with a median survival of 175 days (range 80-453) and 146 patients (46%) either had endoscopic intubation (n = 64) or received no specific treatment (n = 82) with a median survival of 106 days (1-725) and 91 days (1-358) respectively. None of the 182 patients who did not have surgical treatment was alive at five years.

Entities:  

Mesh:

Year:  1994        PMID: 7794305      PMCID: PMC1374841          DOI: 10.1136/gut.35.7.941

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  20 in total

Review 1.  Surgical therapy of oesophageal carcinoma.

Authors:  J M Müller; H Erasmi; M Stelzner; U Zieren; H Pichlmaier
Journal:  Br J Surg       Date:  1990-08       Impact factor: 6.939

2.  Comparison of a single layer continuous hand-sewn method and circular stapling in 580 oesophageal anastomoses.

Authors:  M Fok; A K Ah-Chong; S W Cheng; J Wong
Journal:  Br J Surg       Date:  1991-03       Impact factor: 6.939

3.  Role of pyloroplasty in the retrosternal stomach: results of a prospective, randomized, controlled trial.

Authors:  A Mannell; A McKnight; J D Esser
Journal:  Br J Surg       Date:  1990-01       Impact factor: 6.939

4.  The increasing frequency of adenocarcinoma of the esophagus.

Authors:  P J Hesketh; R W Clapp; W G Doos; S J Spechler
Journal:  Cancer       Date:  1989-07-15       Impact factor: 6.860

5.  En bloc esophagectomy: the first 100 patients.

Authors:  N K Altorki; D B Skinner
Journal:  Hepatogastroenterology       Date:  1990-08

6.  Oesophageal cancer: a population-based study of survival after treatment.

Authors:  S E Oliver; C S Robertson; R F Logan
Journal:  Br J Surg       Date:  1992-12       Impact factor: 6.939

7.  Postoperative radiotherapy for carcinoma of the esophagus: a prospective, randomized controlled study.

Authors:  M Fok; J S Sham; D Choy; S W Cheng; J Wong
Journal:  Surgery       Date:  1993-02       Impact factor: 3.982

8.  Increasing incidence of adenocarcinoma of the esophagus and esophagogastric junction.

Authors:  M Pera; A J Cameron; V F Trastek; H A Carpenter; A R Zinsmeister
Journal:  Gastroenterology       Date:  1993-02       Impact factor: 22.682

9.  Surgical strategies in esophageal carcinoma with emphasis on radical lymphadenectomy.

Authors:  T Lerut; P De Leyn; W Coosemans; D Van Raemdonck; I Scheys; E LeSaffre
Journal:  Ann Surg       Date:  1992-11       Impact factor: 12.969

10.  Increasing incidence of adenocarcinoma of the gastric cardia and adjacent sites.

Authors:  J Powell; C C McConkey
Journal:  Br J Cancer       Date:  1990-09       Impact factor: 7.640

View more
  22 in total

1.  Guidelines for the management of oesophageal and gastric cancer.

Authors:  W H Allum; S M Griffin; A Watson; D Colin-Jones
Journal:  Gut       Date:  2002-06       Impact factor: 23.059

2.  Mid-esophagus unresectable cancer treated with a low cost stent. First experience.

Authors:  Valter N Felix; Alaor Caetano; Jose P Cipullo; Emiliano C Almodova; Wagner Colaiacovo; Aldenir F Zamboti
Journal:  BMC Res Notes       Date:  2011-11-10

3.  The effect of IGF-I receptor blockade for human esophageal squamous cell carcinoma and adenocarcinoma.

Authors:  Yasushi Adachi; Hirokazu Ohashi; Arisa Imsumran; Hiroyuki Yamamoto; Yasutaka Matsunaga; Hiroaki Taniguchi; Katsuhiko Nosho; Hiromu Suzuki; Yasushi Sasaki; Yoshiaki Arimura; David P Carbone; Kohzoh Imai; Yasuhisa Shinomura
Journal:  Tumour Biol       Date:  2013-09-13

Review 4.  Positron Emission Tomography (PET) in Oncology.

Authors:  Andrea Gallamini; Colette Zwarthoed; Anna Borra
Journal:  Cancers (Basel)       Date:  2014-09-29       Impact factor: 6.639

5.  Docetaxel and cisplatin concurrent with radiotherapy versus 5-fluorouracil and cisplatin concurrent with radiotherapy in treatment for locally advanced oesophageal squamous cell carcinoma: a randomized clinical study.

Authors:  Tao Zhao; Hao Chen; Tingrong Zhang
Journal:  Med Oncol       Date:  2012-04-05       Impact factor: 3.064

6.  Current challenges for outcome measurement in surgical practice.

Authors:  M H Williams; J M Blazeby; J I Eachus
Journal:  Ann R Coll Surg Engl       Date:  1995-11       Impact factor: 1.891

7.  Cancer of the oesophagus.

Authors:  S E Oliver; R F Logan
Journal:  Gut       Date:  1995-01       Impact factor: 23.059

8.  Predictive and prognostic value of metabolic tumour volume and total lesion glycolysis in solid tumours.

Authors:  Christophe Van de Wiele; Vibeke Kruse; Peter Smeets; Mike Sathekge; Alex Maes
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-11-14       Impact factor: 9.236

9.  Comparison of oncological outcomes after laparoscopic transhiatal and open esophagectomy for T1 esophageal adenocarcinoma.

Authors:  Arin Kumar Saha; Christopher D Sutton; Henry Sue-Ling; Simon P L Dexter; Abeezar I Sarela
Journal:  Surg Endosc       Date:  2008-07-15       Impact factor: 4.584

10.  Anti-ERBB2 sh-RNA suppress both cell growth and tumor growth in ERBB2-overexpressing upper gastrointestinal adenocarcinomas.

Authors:  Amanda K Arrington; Julia Davydova; Selwyn M Vickers; Masato Yamamoto
Journal:  J Gastrointest Surg       Date:  2009-07-15       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.